25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

VERV (Verve Therapeutics Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Verve Therapeutics Inc together

I guess you are interested in Verve Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Verve Therapeutics Inc’s Financial Insights
  • 📈 Technical Analysis (TA) – Verve Therapeutics Inc’s Price Targets

I'm going to help you getting a better view of Verve Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Verve Therapeutics Inc

I send you an email if I find something interesting about Verve Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Verve Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Verve Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$5.31
Expected worth in 1 year
$4.08
How sure are you?
22.2%

+ What do you gain per year?

Total Gains per Share
$-1.23
Return On Investment
-10.9%

For what price can you sell your share?

Current Price per Share
$11.30
Expected price per share
$8.77 - $20.12
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Verve Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$11.30
Intrinsic Value Per Share
$-8.78 - $-9.84
Total Value Per Share
$-3.47 - $-4.53

2.2. Growth of Verve Therapeutics Inc (5 min.)




Is Verve Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$473.5m$527m-$21.6m-4.3%

How much money is Verve Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$45.2m-$49.2m$3.9m8.7%
Net Profit Margin-487.8%-1,460.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Verve Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#132 / 881

Most Revenue
#252 / 881

Most Profit
#775 / 881

Most Efficient
#657 / 881
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Verve Therapeutics Inc?

Welcome investor! Verve Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Verve Therapeutics Inc.

First you should know what it really means to hold a share of Verve Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Verve Therapeutics Inc is $11.30. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Verve Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Verve Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.31. Based on the TTM, the Book Value Change Per Share is $-0.31 per quarter. Based on the YOY, the Book Value Change Per Share is $0.21 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Verve Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.35-3.1%-0.51-4.5%-0.55-4.9%-0.52-4.6%-0.46-4.0%-0.46-4.0%
Usd Book Value Change Per Share-0.22-2.0%-0.31-2.7%0.211.8%0.131.2%0.302.6%0.302.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.22-2.0%-0.31-2.7%0.211.8%0.131.2%0.302.6%0.302.6%
Usd Price Per Share4.57-4.98-14.81-13.55-18.31-18.31-
Price to Earnings Ratio-3.28--2.53--6.67--6.56--10.74--10.74-
Price-to-Total Gains Ratio-20.48--19.23--86.11-8.17--18.32--18.32-
Price to Book Ratio0.86-0.88-2.57-2.47-3.84-3.84-
Price-to-Total Gains Ratio-20.48--19.23--86.11-8.17--18.32--18.32-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share11.3
Number of shares88
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.310.30
Usd Total Gains Per Share-0.310.30
Gains per Quarter (88 shares)-27.0425.97
Gains per Year (88 shares)-108.15103.88
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-108-118010494
20-216-2260208198
30-324-3340312302
40-433-4420416406
50-541-5500519510
60-649-6580623614
70-757-7660727718
80-865-8740831822
90-973-9820935926
100-1082-1090010391030

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.018.00.00.0%0.018.00.00.0%0.018.00.00.0%
Book Value Change Per Share0.04.00.00.0%3.09.00.025.0%4.014.00.022.2%4.014.00.022.2%4.014.00.022.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.018.00.0%0.00.018.00.0%0.00.018.00.0%
Total Gains per Share0.04.00.00.0%3.09.00.025.0%4.014.00.022.2%4.014.00.022.2%4.014.00.022.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Verve Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.223-0.307+38%0.206-208%0.133-268%0.295-176%0.295-176%
Book Value Per Share--5.3125.669-6%5.912-10%5.641-6%4.595+16%4.595+16%
Current Ratio--9.84312.545-22%16.449-40%14.841-34%17.655-44%17.655-44%
Debt To Asset Ratio--0.2290.230-1%0.216+6%0.204+12%0.332-31%0.332-31%
Debt To Equity Ratio--0.2970.300-1%0.277+7%0.259+15%0.186+59%0.186+59%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--763811424.000827259244.000-8%1719887434.000-56%1593696549.333-52%2212800775.000-65%2212800775.000-65%
Eps---0.348-0.508+46%-0.552+59%-0.521+50%-0.456+31%-0.456+31%
Ev To Ebitda Ratio---5.468-4.231-23%-7.956+46%-8.130+49%-17.532+221%-17.532+221%
Ev To Sales Ratio--5.79121.045-72%129.230-96%215.298-97%215.298-97%215.298-97%
Free Cash Flow Per Share---0.326-0.412+26%-0.420+29%-0.419+29%-0.363+11%-0.363+11%
Free Cash Flow To Equity Per Share---0.326-0.338+4%0.234-239%0.133-346%0.240-236%0.240-236%
Gross Profit Margin--1.0001.008-1%1.016-2%1.008-1%1.005-1%1.005-1%
Intrinsic Value_10Y_max---9.841----------
Intrinsic Value_10Y_min---8.779----------
Intrinsic Value_1Y_max---1.579----------
Intrinsic Value_1Y_min---1.551----------
Intrinsic Value_3Y_max---4.293----------
Intrinsic Value_3Y_min---4.107----------
Intrinsic Value_5Y_max---6.462----------
Intrinsic Value_5Y_min---6.036----------
Market Cap1007318160.000+60%407384424.000444155994.000-8%1319987934.000-69%1207593216.000-66%1631815800.000-75%1631815800.000-75%
Net Profit Margin---0.941-4.878+418%-14.607+1452%-16.763+1681%-11.175+1088%-11.175+1088%
Operating Margin---1.111-5.620+406%-16.652+1399%-19.091+1618%-12.727+1046%-12.727+1046%
Operating Ratio--2.1116.779-69%17.930-88%20.360-90%13.574-84%13.574-84%
Pb Ratio2.127+60%0.8600.881-2%2.566-66%2.469-65%3.839-78%3.839-78%
Pe Ratio-8.115-147%-3.282-2.532-23%-6.674+103%-6.563+100%-10.735+227%-10.735+227%
Price Per Share11.300+60%4.5704.983-8%14.808-69%13.547-66%18.306-75%18.306-75%
Price To Free Cash Flow Ratio-8.663-147%-3.504-3.059-13%-11.315+223%-9.219+163%-16.190+362%-16.190+362%
Price To Total Gains Ratio-50.652-147%-20.485-19.232-6%-86.111+320%8.169-351%-18.319-11%-18.319-11%
Quick Ratio--17.29521.139-18%28.619-40%25.300-32%27.905-38%27.905-38%
Return On Assets---0.051-0.069+36%-0.074+47%-0.075+48%-0.090+78%-0.090+78%
Return On Equity---0.066-0.089+36%-0.095+45%-0.093+42%-0.082+26%-0.082+26%
Total Gains Per Share---0.223-0.307+38%0.206-208%0.133-268%0.295-176%0.295-176%
Usd Book Value--473513000.000505389500.000-6%527040500.000-10%502867000.000-6%409618722.222+16%409618722.222+16%
Usd Book Value Change Per Share---0.223-0.307+38%0.206-208%0.133-268%0.295-176%0.295-176%
Usd Book Value Per Share--5.3125.669-6%5.912-10%5.641-6%4.595+16%4.595+16%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--763811424.000827259244.000-8%1719887434.000-56%1593696549.333-52%2212800775.000-65%2212800775.000-65%
Usd Eps---0.348-0.508+46%-0.552+59%-0.521+50%-0.456+31%-0.456+31%
Usd Free Cash Flow---29069000.000-36745500.000+26%-37469000.000+29%-37373166.667+29%-32392222.222+11%-32392222.222+11%
Usd Free Cash Flow Per Share---0.326-0.412+26%-0.420+29%-0.419+29%-0.363+11%-0.363+11%
Usd Free Cash Flow To Equity Per Share---0.326-0.338+4%0.234-239%0.133-346%0.240-236%0.240-236%
Usd Market Cap1007318160.000+60%407384424.000444155994.000-8%1319987934.000-69%1207593216.000-66%1631815800.000-75%1631815800.000-75%
Usd Price Per Share11.300+60%4.5704.983-8%14.808-69%13.547-66%18.306-75%18.306-75%
Usd Profit---31033000.000-45251500.000+46%-49207250.000+59%-45902583.333+48%-40171277.778+29%-40171277.778+29%
Usd Revenue--32976000.00014903250.000+121%4012250.000+722%6583916.667+401%4389277.778+651%4389277.778+651%
Usd Total Gains Per Share---0.223-0.307+38%0.206-208%0.133-268%0.295-176%0.295-176%
 EOD+5 -3MRQTTM+24 -14YOY+16 -223Y+15 -235Y+19 -1910Y+19 -19

3.3 Fundamental Score

Let's check the fundamental score of Verve Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-8.115
Price to Book Ratio (EOD)Between0-12.127
Net Profit Margin (MRQ)Greater than0-0.941
Operating Margin (MRQ)Greater than0-1.111
Quick Ratio (MRQ)Greater than117.295
Current Ratio (MRQ)Greater than19.843
Debt to Asset Ratio (MRQ)Less than10.229
Debt to Equity Ratio (MRQ)Less than10.297
Return on Equity (MRQ)Greater than0.15-0.066
Return on Assets (MRQ)Greater than0.05-0.051
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Verve Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5085.362
Ma 20Greater thanMa 507.927
Ma 50Greater thanMa 1006.030
Ma 100Greater thanMa 2006.034
OpenGreater thanClose11.225
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Verve Therapeutics Inc

Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. The company's product candidates include VERVE-101, which is being evaluated in the Heart-1 trial, an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C levels in patients living with heterozygous familial hypercholesterolemia (HeFH); VERVE-102 that is being evaluated in the Heart-2 trial, an open-label Phase 1b clinical trial in adult patients with HeFH, and/or premature coronary artery diseases; VERVE-201, which targets ANGPTL3 and permanently turn off the ANGPTL3 gene in the liver; and VERVE-301, a development candidate that uses a novel in vivo gene editing approach to permanently turn off the LPA gene in the liver to reduce blood Lp(a) levels. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; a license agreement to lipid technology with Novartis Pharma AG; Eli Lilly and Company; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is based in Boston, Massachusetts.

Fundamental data was last updated by Penke on 2025-06-20 18:47:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Verve Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Verve Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -94.1% means that $-0.94 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Verve Therapeutics Inc:

  • The MRQ is -94.1%. The company is making a huge loss. -2
  • The TTM is -487.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-94.1%TTM-487.8%+393.7%
TTM-487.8%YOY-1,460.7%+973.0%
TTM-487.8%5Y-1,117.5%+629.8%
5Y-1,117.5%10Y-1,117.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-94.1%-88.2%-5.9%
TTM-487.8%-141.5%-346.3%
YOY-1,460.7%-182.9%-1,277.8%
3Y-1,676.3%-247.7%-1,428.6%
5Y-1,117.5%-338.6%-778.9%
10Y-1,117.5%-473.1%-644.4%
4.3.1.2. Return on Assets

Shows how efficient Verve Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Verve Therapeutics Inc to the Biotechnology industry mean.
  • -5.1% Return on Assets means that Verve Therapeutics Inc generated $-0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Verve Therapeutics Inc:

  • The MRQ is -5.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.1%TTM-6.9%+1.8%
TTM-6.9%YOY-7.4%+0.6%
TTM-6.9%5Y-9.0%+2.2%
5Y-9.0%10Y-9.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.1%-11.1%+6.0%
TTM-6.9%-11.2%+4.3%
YOY-7.4%-11.0%+3.6%
3Y-7.5%-11.6%+4.1%
5Y-9.0%-11.8%+2.8%
10Y-9.0%-13.6%+4.6%
4.3.1.3. Return on Equity

Shows how efficient Verve Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Verve Therapeutics Inc to the Biotechnology industry mean.
  • -6.6% Return on Equity means Verve Therapeutics Inc generated $-0.07 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Verve Therapeutics Inc:

  • The MRQ is -6.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -8.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.6%TTM-8.9%+2.4%
TTM-8.9%YOY-9.5%+0.6%
TTM-8.9%5Y-8.2%-0.7%
5Y-8.2%10Y-8.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.6%-12.8%+6.2%
TTM-8.9%-14.2%+5.3%
YOY-9.5%-14.1%+4.6%
3Y-9.3%-16.6%+7.3%
5Y-8.2%-17.3%+9.1%
10Y-8.2%-19.4%+11.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Verve Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Verve Therapeutics Inc is operating .

  • Measures how much profit Verve Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Verve Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -111.1% means the company generated $-1.11  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Verve Therapeutics Inc:

  • The MRQ is -111.1%. The company is operating very inefficient. -2
  • The TTM is -562.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-111.1%TTM-562.0%+450.9%
TTM-562.0%YOY-1,665.2%+1,103.2%
TTM-562.0%5Y-1,272.7%+710.7%
5Y-1,272.7%10Y-1,272.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-111.1%-227.4%+116.3%
TTM-562.0%-253.9%-308.1%
YOY-1,665.2%-201.7%-1,463.5%
3Y-1,909.1%-214.9%-1,694.2%
5Y-1,272.7%-339.9%-932.8%
10Y-1,272.7%-444.7%-828.0%
4.3.2.2. Operating Ratio

Measures how efficient Verve Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.11 means that the operating costs are $2.11 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Verve Therapeutics Inc:

  • The MRQ is 2.111. The company is inefficient in keeping operating costs low. -1
  • The TTM is 6.779. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.111TTM6.779-4.668
TTM6.779YOY17.930-11.152
TTM6.7795Y13.574-6.795
5Y13.57410Y13.5740.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1112.060+0.051
TTM6.7792.737+4.042
YOY17.9302.997+14.933
3Y20.3603.496+16.864
5Y13.5744.660+8.914
10Y13.5746.353+7.221
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Verve Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Verve Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 9.84 means the company has $9.84 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Verve Therapeutics Inc:

  • The MRQ is 9.843. The company is very able to pay all its short-term debts. +2
  • The TTM is 12.545. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.843TTM12.545-2.702
TTM12.545YOY16.449-3.904
TTM12.5455Y17.655-5.110
5Y17.65510Y17.6550.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.8433.670+6.173
TTM12.5453.745+8.800
YOY16.4494.121+12.328
3Y14.8414.623+10.218
5Y17.6555.733+11.922
10Y17.6556.143+11.512
4.4.3.2. Quick Ratio

Measures if Verve Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Verve Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 17.29 means the company can pay off $17.29 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Verve Therapeutics Inc:

  • The MRQ is 17.295. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 21.139. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ17.295TTM21.139-3.844
TTM21.139YOY28.619-7.480
TTM21.1395Y27.905-6.766
5Y27.90510Y27.9050.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.2952.906+14.389
TTM21.1393.128+18.011
YOY28.6193.786+24.833
3Y25.3004.308+20.992
5Y27.9055.703+22.202
10Y27.9056.411+21.494
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Verve Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Verve Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Verve Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.23 means that Verve Therapeutics Inc assets are financed with 22.9% credit (debt) and the remaining percentage (100% - 22.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Verve Therapeutics Inc:

  • The MRQ is 0.229. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.230. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.229TTM0.230-0.001
TTM0.230YOY0.216+0.014
TTM0.2305Y0.332-0.102
5Y0.33210Y0.3320.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2290.328-0.099
TTM0.2300.356-0.126
YOY0.2160.335-0.119
3Y0.2040.339-0.135
5Y0.3320.350-0.018
10Y0.3320.383-0.051
4.5.4.2. Debt to Equity Ratio

Measures if Verve Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Verve Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 29.7% means that company has $0.30 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Verve Therapeutics Inc:

  • The MRQ is 0.297. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.300. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.297TTM0.300-0.002
TTM0.300YOY0.277+0.022
TTM0.3005Y0.186+0.113
5Y0.18610Y0.1860.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2970.384-0.087
TTM0.3000.436-0.136
YOY0.2770.413-0.136
3Y0.2590.447-0.188
5Y0.1860.464-0.278
10Y0.1860.512-0.326
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Verve Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Verve Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -3.28 means the investor is paying $-3.28 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Verve Therapeutics Inc:

  • The EOD is -8.115. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.282. Based on the earnings, the company is expensive. -2
  • The TTM is -2.532. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.115MRQ-3.282-4.833
MRQ-3.282TTM-2.532-0.750
TTM-2.532YOY-6.674+4.142
TTM-2.5325Y-10.735+8.203
5Y-10.73510Y-10.7350.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.115-2.125-5.990
MRQ-3.282-2.027-1.255
TTM-2.532-2.541+0.009
YOY-6.674-3.670-3.004
3Y-6.563-3.716-2.847
5Y-10.735-6.057-4.678
10Y-10.735-6.591-4.144
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Verve Therapeutics Inc:

  • The EOD is -8.663. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.504. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.059. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.663MRQ-3.504-5.160
MRQ-3.504TTM-3.059-0.445
TTM-3.059YOY-11.315+8.256
TTM-3.0595Y-16.190+13.131
5Y-16.19010Y-16.1900.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.663-3.030-5.633
MRQ-3.504-2.710-0.794
TTM-3.059-3.805+0.746
YOY-11.315-4.404-6.911
3Y-9.219-5.103-4.116
5Y-16.190-8.536-7.654
10Y-16.190-9.228-6.962
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Verve Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.86 means the investor is paying $0.86 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Verve Therapeutics Inc:

  • The EOD is 2.127. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.860. Based on the equity, the company is cheap. +2
  • The TTM is 0.881. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD2.127MRQ0.860+1.267
MRQ0.860TTM0.881-0.021
TTM0.881YOY2.566-1.685
TTM0.8815Y3.839-2.958
5Y3.83910Y3.8390.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.1271.900+0.227
MRQ0.8601.861-1.001
TTM0.8812.162-1.281
YOY2.5662.465+0.101
3Y2.4692.527-0.058
5Y3.8393.682+0.157
10Y3.8394.351-0.512
4.6.2. Total Gains per Share

2.4. Latest News of Verve Therapeutics Inc

Does Verve Therapeutics Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Verve Therapeutics Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-26
23:20
BMO Capital downgrades Verve Therapeutics stock on Eli Lilly acquisitionRead
2025-06-23
07:40
Lilly To Acquire Verve For One-Time Cardiovascular TreatmentsRead
2025-06-23
06:05
Eli Lilly Diversifies With Verve Gene Therapy DealRead
2025-06-22
15:05
Notable healthcare headlines for the week: Eli Lilly, Novavax and Sarepta Therapeutics in focusRead
2025-06-21
21:15
Key deals this week: Couchbase, Eli Lilly, NTT Data, QXO, US Steel and moreRead
2025-06-21
19:21
Trending stocks in mixed week for U.S. marketRead
2025-06-20
19:07
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This WeekRead
2025-06-18
11:32
Eli Lilly acquisition of Verve signals renewed interest in gene editingRead
2025-06-18
08:57
Jefferies cuts Verve Therapeutics stock rating on Lilly acquisition newsRead
2025-06-17
14:20
Stocks making the biggest moves premarket: Sunrun, Verve Therapeutics, T-Mobile and moreRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Verve Therapeutics Inc.

4.8.1. Institutions holding Verve Therapeutics Inc

Institutions are holding 94.63% of the shares of Verve Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Alphabet Inc13.85313.57861234908600
2025-03-31BlackRock Inc8.83770.000878782363527664.6876
2025-03-31Bvf Inc7.74491.2859690405000
2025-03-31Casdin Capital, LLC4.48221.4921399557100
2025-03-31Vanguard Group Inc4.43680.00033955099-51535-1.2862
2024-12-31Schonfeld Strategic Advisors LLC4.25090.12433789379138217657.4183
2025-03-31State Street Corp3.46770.00063091189-144558-4.4675
2025-03-31Novo A/S3.36541.0429300000060000025
2025-03-31Woodline Partners LP3.10480.0823276771927677190
2025-03-31T. Rowe Price Investment Management,Inc.2.79540.007524919491393505.9232
2025-03-31Millennium Management LLC2.36780.00512110774-1808357-46.1418
2025-03-31ARCH VENTURE CORP2.25354.4225200880900
2025-03-31Baker Bros Advisors LP1.89750.0855169153000
2025-03-31Geode Capital Management, LLC1.88730.00061682391566113.4821
2025-03-31Bank of America Corp1.83170.000616328761085205198.1491
2025-03-31FMR Inc1.59410.0004142099142260.2983
2025-03-31Goldman Sachs Group Inc1.58520.0011141311867193990.6581
2025-03-31Point72 Asset Management, L.P.1.56310.01451393398-718-0.0515
2025-03-31Nuveen, LLC1.4860.0018132466913246690
2024-12-31Nuveen Asset Management, LLC1.4760.00211315771-355953-21.2926
Total 74.281112.149566216605+6023540+9.1%

4.9.2. Funds holding Verve Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Vanguard Total Stock Mkt Idx Inv2.78350.0008248132335053016.4507
2025-05-31iShares Russell 2000 ETF1.97910.0128176421800
2025-05-31SPDR® S&P Biotech ETF1.45340.1229129557276580.5946
2025-03-31T. Rowe Price Small-Cap Value1.31740.05611174386-252-0.0215
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr1.18350.0059105500323010.2186
2025-04-30Nuveen Quant Small Cap Equity R61.05190.1727937680-23320-2.4266
2025-03-31Fidelity Small Cap Index0.79790.013571125632390.4575
2025-03-31T. Rowe Price U.S. SC Value Eq Tr-D0.76160.0553678953492057.8134
2025-05-31iShares Russell 2000 Value ETF0.72960.02765034600
2025-05-31State St Russell Sm/Mid Cp® Indx SL Cl I0.47070.004541957200
2025-04-30BlackRock Advantage Small Cap Core Instl0.45740.061740771600
2025-05-31iShares Biotechnology ETF0.4330.034438602000
2025-04-30Fidelity Extended Market Index0.41740.0059372081-3556-0.9467
2025-04-30JPMorgan US Small Company L0.40230.24133586293586290
2025-04-30Vanguard Russell 2000 ETF0.39520.0169352273197405.9363
2025-04-30T. Rowe Price US Smlr Coms Eq A0.37330.0477332797-17084-4.8828
2025-05-31Schwab US Small-Cap ETF™0.36180.0087322504-851-0.2632
2025-05-31Selectra J. Lamarck Biotech A0.3592.1967320000160000100
2025-04-30JPM Thematics Genetic Thrps C2 dist USD0.29880.4049266402-6464-2.3689
2025-05-31State St Russell Sm Cap® Indx SL Cl I0.27350.012524378600
Total 16.30033.502214530517+899775+6.2%

5.3. Insider Transactions

Insiders are holding 5.104% of the shares of Verve Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-04-02Allison DorvalSELL33504.15
2025-04-02Joan NickersonSELL27774.15
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets614,163
Total Liabilities140,650
Total Stockholder Equity473,513
 As reported
Total Liabilities 140,650
Total Stockholder Equity+ 473,513
Total Assets = 614,163

Assets

Total Assets614,163
Total Current Assets511,650
Long-term Assets102,513
Total Current Assets
Cash And Cash Equivalents 96,554
Short-term Investments 400,523
Net Receivables 1,399
Other Current Assets 13,174
Total Current Assets  (as reported)511,650
Total Current Assets  (calculated)511,650
+/-0
Long-term Assets
Property Plant Equipment 94,674
Long-term Assets Other 7,839
Long-term Assets  (as reported)102,513
Long-term Assets  (calculated)102,513
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities51,981
Long-term Liabilities88,669
Total Stockholder Equity473,513
Total Current Liabilities
Short-term Debt 10,516
Accounts payable 5,352
Other Current Liabilities 17,053
Total Current Liabilities  (as reported)51,981
Total Current Liabilities  (calculated)32,921
+/- 19,060
Long-term Liabilities
Capital Lease Obligations 68,636
Long-term Liabilities Other 1,029
Long-term Liabilities  (as reported)88,669
Long-term Liabilities  (calculated)69,665
+/- 19,004
Total Stockholder Equity
Common Stock89
Retained Earnings -774,047
Accumulated Other Comprehensive Income 393
Other Stockholders Equity 1,247,078
Total Stockholder Equity (as reported)473,513
Total Stockholder Equity (calculated)473,513
+/-0
Other
Capital Stock89
Cash and Short Term Investments 497,077
Common Stock Shares Outstanding 88,796
Current Deferred Revenue19,060
Liabilities and Stockholders Equity 614,163
Net Debt -27,918
Net Invested Capital 473,513
Net Working Capital 459,669
Property Plant and Equipment Gross 113,498
Short Long Term Debt Total 68,636



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
78,413
158,169
426,518
410,877
384,124
349,241
324,267
673,355
679,223
634,376
589,131
612,407
752,688
732,357
700,910
663,906
647,392
614,163
614,163647,392663,906700,910732,357752,688612,407589,131634,376679,223673,355324,267349,241384,124410,877426,518158,16978,413000
   > Total Current Assets 
18,782
0
0
73,966
151,841
419,564
394,437
367,128
328,830
298,644
561,630
563,159
508,687
473,066
498,261
637,949
620,326
590,887
556,459
542,751
511,650
511,650542,751556,459590,887620,326637,949498,261473,066508,687563,159561,630298,644328,830367,128394,437419,564151,84173,9660018,782
       Cash And Cash Equivalents 
-18,782
0
0
8,993
99,397
387,446
148,134
64,330
91,420
72,889
550,710
115,412
508,687
70,042
78,370
206,180
144,200
141,490
158,709
172,560
96,554
96,554172,560158,709141,490144,200206,18078,37070,042508,687115,412550,71072,88991,42064,330148,134387,44699,3978,99300-18,782
       Short-term Investments 
37,564
0
0
63,119
50,126
30,178
241,076
296,112
231,879
220,672
273,691
439,396
424,941
392,434
406,856
417,770
462,167
434,458
381,211
351,721
400,523
400,523351,721381,211434,458462,167417,770406,856392,434424,941439,396273,691220,672231,879296,112241,07630,17850,12663,1190037,564
       Net Receivables 
0
0
0
0
0
0
0
2,696
0
0
929
1,012
1,404
2,093
3,145
5,897
5,767
3,040
2,628
3,255
1,399
1,3993,2552,6283,0405,7675,8973,1452,0931,4041,012929002,6960000000
       Other Current Assets 
0
0
0
1,854
2,318
3,880
10,454
13,372
11,062
10,166
9,991
7,339
7,696
8,497
9,890
8,102
8,192
11,899
13,911
15,215
13,174
13,17415,21513,91111,8998,1928,1029,8908,4977,6967,3399,99110,16611,06213,37210,4543,8802,3181,854000
   > Long-term Assets 
-18,782
0
0
4,447
6,328
6,954
16,440
16,996
20,411
25,623
111,725
116,064
125,689
116,065
114,146
114,739
112,031
110,023
107,447
104,641
102,513
102,513104,641107,447110,023112,031114,739114,146116,065125,689116,064111,72525,62320,41116,99616,4406,9546,3284,44700-18,782
       Property Plant Equipment 
0
0
0
3,984
5,202
6,417
8,909
9,063
12,472
13,193
106,491
110,655
111,056
110,018
107,844
107,800
104,551
101,931
99,546
96,726
94,674
94,67496,72699,546101,931104,551107,800107,844110,018111,056110,655106,49113,19312,4729,0638,9096,4175,2023,984000
       Long-term Assets Other 
-18,782
0
0
463
663
74
2,294
2,696
2,702
7,193
410
585
9,809
1,223
1,528
2,165
2,706
3,318
7,901
7,915
7,839
7,8397,9157,9013,3182,7062,1651,5281,2239,8095854107,1932,7022,6962,2947466346300-18,782
> Total Liabilities 
0
0
0
142,322
234,600
21,122
25,942
26,772
17,851
27,934
125,412
128,291
124,900
123,909
152,038
153,186
149,288
154,816
155,355
153,992
140,650
140,650153,992155,355154,816149,288153,186152,038123,909124,900128,291125,41227,93417,85126,77225,94221,122234,600142,322000
   > Total Current Liabilities 
0
0
0
7,315
6,684
8,649
20,251
22,024
14,803
25,847
29,018
35,095
33,552
33,031
34,575
37,006
31,294
40,367
42,642
42,909
51,981
51,98142,90942,64240,36731,29437,00634,57533,03133,55235,09529,01825,84714,80322,02420,2518,6496,6847,315000
       Short-term Debt 
0
0
0
0
0
0
4,590
1,955
2,864
1,814
17,808
23,808
22,368
20,092
20,236
20,384
10,220
20,586
20,736
20,884
10,516
10,51620,88420,73620,58610,22020,38420,23620,09222,36823,80817,8081,8142,8641,9554,590000000
       Accounts payable 
0
0
0
36
2,487
1,530
3,579
7,077
2,438
6,320
465
2,424
3,372
3,146
1,054
6,636
3,049
6,833
4,637
4,520
5,352
5,3524,5204,6376,8333,0496,6361,0543,1463,3722,4244656,3202,4387,0773,5791,5302,48736000
       Other Current Liabilities 
0
0
0
7,279
4,061
7,119
12,082
12,992
9,501
17,713
10,745
8,863
7,812
9,793
13,285
9,986
16,552
19,218
21,918
24,342
17,053
17,05324,34221,91819,21816,5529,98613,2859,7937,8128,86310,74517,7139,50112,99212,0827,1194,0617,279000
   > Long-term Liabilities 
0
0
0
135,007
227,916
12,473
5,691
4,748
3,048
2,087
96,394
93,196
91,348
90,878
117,463
116,180
117,994
114,449
112,713
111,083
88,669
88,669111,083112,713114,449117,994116,180117,46390,87891,34893,19696,3942,0873,0484,7485,69112,473227,916135,007000
       Other Liabilities 
0
0
0
0
8,997
12,473
5,510
4,748
3,048
2,087
25,383
23,182
0
23,059
0
0
0
0
0
0
0
000000023,059023,18225,3832,0873,0484,7485,51012,4738,9970000
       Deferred Long Term Liability 
0
0
0
0
663
13
0
0
0
0
20,014
20,014
20,014
0
0
0
0
0
0
0
0
0000000020,01420,01420,0140000136630000
> Total Stockholder Equity
5,927
0
0
-63,909
-76,431
405,396
384,935
357,352
331,390
296,333
547,943
550,932
509,476
465,222
460,369
599,502
583,069
546,094
508,551
493,400
473,513
473,513493,400508,551546,094583,069599,502460,369465,222509,476550,932547,943296,333331,390357,352384,935405,396-76,431-63,909005,927
   Common Stock
0
0
0
3
3
48
48
49
49
49
61
62
62
62
64
82
84
85
85
89
89
8989858584826462626261494949484833000
   Retained Earnings -774,047-743,014-692,979-642,846-593,041-544,305-495,953-450,195-396,212-344,237-303,152-257,962-217,016-186,850-155,513-132,764-79,799-66,536000
   Capital Surplus 
0
0
0
0
0
538,109
540,402
544,381
549,089
555,184
851,954
895,801
905,863
0
0
0
0
0
0
0
0
00000000905,863895,801851,954555,184549,089544,381540,402538,10900000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
0
0
0
2,616
3,358
538,109
540,402
544,381
549,089
555,184
851,954
895,801
905,863
916,109
956,855
1,143,453
1,176,526
1,189,470
1,200,302
1,235,897
1,247,078
1,247,0781,235,8971,200,3021,189,4701,176,5261,143,453956,855916,109905,863895,801851,954555,184549,089544,381540,402538,1093,3582,616000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue32,332
Cost of Revenue-6,753
Gross Profit32,33225,579
 
Operating Income (+$)
Gross Profit32,332
Operating Expense-260,992
Operating Income-228,660-228,660
 
Operating Expense (+$)
Research Development204,347
Selling General Administrative56,645
Selling And Marketing Expenses0
Operating Expense260,992260,992
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-28,762
Net Interest Income28,762
 
Pretax Income (+$)
Operating Income-228,660
Net Interest Income28,762
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-198,360-258,960
EBIT - interestExpense = -228,660
-198,360
-198,709
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-228,660-198,360
Earnings Before Interest and Taxes (EBITDA)-221,907
 
After tax Income (+$)
Income Before Tax-198,360
Tax Provision-349
Net Income From Continuing Ops-198,709-198,709
Net Income-198,709
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses260,992
Total Other Income/Expenses Net30,300-28,762
 

Technical Analysis of Verve Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Verve Therapeutics Inc. The general trend of Verve Therapeutics Inc is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Verve Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Verve Therapeutics Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Verve Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 11.41 < 19.34 < 20.12.

The bearish price targets are: 9.305 > 8.77 > 8.77.

Know someone who trades $VERV? Share this with them.👇

Verve Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Verve Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Verve Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Verve Therapeutics Inc. The current macd is 1.7423967.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Verve Therapeutics Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Verve Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Verve Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Verve Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartVerve Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Verve Therapeutics Inc. The current adx is 48.45.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Verve Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Verve Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Verve Therapeutics Inc. The current sar is 9.19488965.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Verve Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Verve Therapeutics Inc. The current rsi is 85.36. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Verve Therapeutics Inc Daily Relative Strength Index (RSI) ChartVerve Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Verve Therapeutics Inc. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Verve Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Verve Therapeutics Inc Daily Stochastic Oscillator ChartVerve Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Verve Therapeutics Inc. The current cci is 85.98.

Verve Therapeutics Inc Daily Commodity Channel Index (CCI) ChartVerve Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Verve Therapeutics Inc. The current cmo is 78.35.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Verve Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartVerve Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Verve Therapeutics Inc. The current willr is -1.86666667.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Verve Therapeutics Inc Daily Williams %R ChartVerve Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Verve Therapeutics Inc.

Verve Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Verve Therapeutics Inc. The current atr is 0.54614862.

Verve Therapeutics Inc Daily Average True Range (ATR) ChartVerve Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Verve Therapeutics Inc. The current obv is 134,907,134.

Verve Therapeutics Inc Daily On-Balance Volume (OBV) ChartVerve Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Verve Therapeutics Inc. The current mfi is 81.63.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Verve Therapeutics Inc Daily Money Flow Index (MFI) ChartVerve Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Verve Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-02-25BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-31BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-01MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-03BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-11MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-23STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Verve Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Verve Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5085.362
Ma 20Greater thanMa 507.927
Ma 50Greater thanMa 1006.030
Ma 100Greater thanMa 2006.034
OpenGreater thanClose11.225
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Verve Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Verve Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Verve Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Verve Therapeutics Inc

I send you an email if I find something interesting about Verve Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Verve Therapeutics Inc.

Receive notifications about Verve Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.